This review summarises pooled analysis of survival data from 4 nivolumab CheckMate studies in patients with previously treated advanced NSCLC.
A total of 644 patients were included in the analysis and independent commentary is provided by Dr Thomas John, a medical oncologist and translational researcher at Austin Health and the Ludwig Institute for Cancer Research.
Please login below to download this issue (PDF)